136 related articles for article (PubMed ID: 7625815)
21. Susceptibility of Brucella melitensis to fluoroquinolones.
Qadri SM; Akhtar M; Ueno Y; al-Sibai MB
Drugs Exp Clin Res; 1989; 15(10):483-5. PubMed ID: 2632216
[TBL] [Abstract][Full Text] [Related]
22. Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method.
Kenny GE; Hooton TM; Roberts MC; Cartwright FD; Hoyt J
Antimicrob Agents Chemother; 1989 Jan; 33(1):103-7. PubMed ID: 2712541
[TBL] [Abstract][Full Text] [Related]
23. In-vitro activity of four new fluoroquinolones.
García-Rodríguez JA; García Sánchez JE; García García MI; Fresnadillo MJ; Trujillano I; García Sánchez E
J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215
[TBL] [Abstract][Full Text] [Related]
24. Anti-Mycobacterium avium activity of quinolones: in vitro activities.
Klopman G; Wang S; Jacobs MR; Bajaksouzian S; Edmonds K; Ellner JJ
Antimicrob Agents Chemother; 1993 Sep; 37(9):1799-806. PubMed ID: 8239587
[TBL] [Abstract][Full Text] [Related]
25. In vitro activity of sparfloxacin and clinafloxacin against multidrug-resistant enterococci.
Perri MB; Chow JW; Zervos MJ
Diagn Microbiol Infect Dis; 1993; 17(2):151-5. PubMed ID: 8243036
[TBL] [Abstract][Full Text] [Related]
26. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes.
Spangler SK; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1994 Oct; 38(10):2471-6. PubMed ID: 7840591
[TBL] [Abstract][Full Text] [Related]
27. In vitro antimicrobial susceptibility of Brucella species.
Baykam N; Esener H; Ergönül O; Eren S; Celikbas AK; Dokuzoguz B
Int J Antimicrob Agents; 2004 Apr; 23(4):405-7. PubMed ID: 15081093
[TBL] [Abstract][Full Text] [Related]
28. In vitro activity of BAY 12-8039, a new fluoroquinolone.
Woodcock JM; Andrews JM; Boswell FJ; Brenwald NP; Wise R
Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
[TBL] [Abstract][Full Text] [Related]
29. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
[TBL] [Abstract][Full Text] [Related]
30. In vitro and in vivo activities of clinafloxacin, CI-990 (PD 131112), and PD 138312 versus enterococci.
Cohen MA; Yoder SL; Huband MD; Roland GE; Courtney CL
Antimicrob Agents Chemother; 1995 Sep; 39(9):2123-7. PubMed ID: 8540728
[TBL] [Abstract][Full Text] [Related]
31. In vitro and in vivo evaluations of A-80556, a new fluoroquinolone.
Clement JJ; Tanaka SK; Alder J; Vojtko C; Beyer J; Hensey D; Ramer N; McDaniel D; Chu DT
Antimicrob Agents Chemother; 1994 May; 38(5):1071-8. PubMed ID: 8067740
[TBL] [Abstract][Full Text] [Related]
32. Modifications for disk diffusion susceptibility testing criteria of clinafloxacin (CI-960, AM-1091, PD127371) and fleroxacin (Ro 23-6240, AM-833) following studies with a challenge panel of ciprofloxacin-resistant clinical isolates.
Jones RN; Johnson DM
Diagn Microbiol Infect Dis; 1995 Apr; 21(4):209-13. PubMed ID: 7554803
[TBL] [Abstract][Full Text] [Related]
33. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
Barry AL; Fuchs PC
Antimicrob Agents Chemother; 1991 May; 35(5):955-60. PubMed ID: 1906696
[TBL] [Abstract][Full Text] [Related]
34. In-vitro activity of clinafloxacin (CI-960) and PD 131628-2 against anaerobic bacteria.
Wexler HM; Molitoris E; Reeves D; Finegold SM
J Antimicrob Chemother; 1994 Oct; 34(4):579-84. PubMed ID: 7868409
[TBL] [Abstract][Full Text] [Related]
35. Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin.
Gorzynski EA; Gutman SI; Allen W
Antimicrob Agents Chemother; 1989 Apr; 33(4):591-2. PubMed ID: 2524998
[TBL] [Abstract][Full Text] [Related]
36. Comparative in vitro activities of new quinolones against coryneform bacteria.
Martínez-Martínez L; Suárez AI; Ortega MC; Perea EJ
Antimicrob Agents Chemother; 1994 Jun; 38(6):1439-41. PubMed ID: 8092851
[TBL] [Abstract][Full Text] [Related]
37. [Activity of new quinolones against clinical isolates of Corynebacterium species].
Yagüe Guirao G; Martínez-Toldos MC; Mora Peris B; López Domínguez R; Romero Otero M; Muñoz Bellido JL; Segovia Hernández M
Rev Esp Quimioter; 2000 Sep; 13(3):267-70. PubMed ID: 11086275
[TBL] [Abstract][Full Text] [Related]
38. Activities of three investigational fluoroquinolones (BAY y 3118, DU-6859a, and clinafloxacin) against Neisseria gonorrhoeae isolates with diminished susceptibilities to ciprofloxacin and ofloxacin.
Carlyn CJ; Doyle LJ; Knapp CC; Ludwig MD; Washington JA
Antimicrob Agents Chemother; 1995 Jul; 39(7):1606-8. PubMed ID: 7492114
[TBL] [Abstract][Full Text] [Related]
39. Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure.
Peterson ML; Hovde LB; Wright DH; Hoang AD; Raddatz JK; Boysen PJ; Rotschafer JC
Antimicrob Agents Chemother; 1999 Sep; 43(9):2251-5. PubMed ID: 10471574
[TBL] [Abstract][Full Text] [Related]
40. Activity of clinafloxacin against multidrug-resistant Enterococcus faecium.
Burney S; Landman D; Quale JM
Antimicrob Agents Chemother; 1994 Jul; 38(7):1668-70. PubMed ID: 7979306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
